Learn more about Janssen’s COVID-19 response and our continued support to help patients afford and access our medicines.[x]

Start with OPSUMIT® (macitentan) to reduce the risks of disease progression and hospitalization for PAH1

In the treatment of pulmonary arterial hypertension (PAH, WHO Group I)

home-header-img-mobile
Learn more about OPSUMIT clinical data

View overall results from the SERAPHIN pivotal trial

Looking for patient enrollment resources?

Get patients started on OPSUMIT

See SERAPHIN PAH-related hospitalization data

View PAH-related hospitalization data

Need downloadable resources?

View our library of downloadable materials for HCPs and patients

Explore SERAPHIN PAH-CTD subgroup data

View PAH-CTD subgroup post hoc analyses

Watch patient and HCP perspectives on PAH

Access the video library

PAH=pulmonary arterial hypertension; PAH-CTD=PAH associated with connective tissue disease; SERAPHIN=Study with an Endothelin Receptor Antagonist in Pulmonary Arterial Hypertension to Improve CliNical Outcome; WHO=World Health Organization.